Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.79 0.13 (0.53%) Market Cap: 3.07 Bil Enterprise Value: 2.91 Bil PE Ratio: 0 PB Ratio: 17.46 GF Score: 53/100

Arrowhead Pharmaceuticals Inc to Present Topline Data from the Phase 2 SEQUOIA Study Transcript

Jan 09, 2023 / 01:30PM GMT
Release Date Price: €34.78 (-0.56%)
Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR & VP

Hi, everybody. Thanks for joining us today. We are here to talk about the Fazirsiran SEQUOIA top line results and give an outline for what the Phase III looks like. So thanks all for joining us this early in the morning. Next slide, please.

Just before we start, I want to make sure everybody knows that we will be making forward-looking statements, so please refer to our SEC filings for the risk factors.

Next slide. Today on the panel, we have Dr. Virginia Clark from the University of Florida, who's going to talk about AAT and natural history of the disease as well as some of the significance of the findings from the SEQUOIA study. Myself, I'm Vince Anzalone, the Vice President of Investor Relations; and Javier San Martin, our Chief Medical Officer.

Next slide. So today, we -- as I mentioned, Javier is going to speak about the Fazirsiran SEQUOIA top line results. Dr. Clark will then provide some context about why this is important. Javier will go back into the Phase III design, and then we'll give some

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot